Results 111 to 120 of about 8,597,475 (170)

Clinical Outcomes of High-Dose Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Bousamri A, Al-Shehri M, Mestarihi M, Almutairi TB, Alaredhi M, Mahanna B, Alharbi F.   +6 more
europepmc   +1 more source

Therapeutic landscape for diabetic macular edema: durable strategies with a focus on aflibercept 8 mg

To evaluate current therapies for diabetic macular edema (DME), with emphasis on durability, safety, access, and the evidence supporting aflibercept 8 mg. An expert-selected narrative synthesis of primary clinical trials, pharmacologic studies, regulatory documents, and selected real-world evidence published from January 1, 2000, through August 8, 2026,
Basile-Alvarez, Martín Roberto, Escalante-Buendía, Erick André, Palacios-Aguirre, Karen A., Ortega Desio, Alejandro, Bello-Chavolla, Omar Yaxmehen   +4 more
openaire   +1 more source

SPECTRUM: Early clinical experience from the first global real-world study of aflibercept 8 mg in patients with diabetic macular oedema. [PDF]

Eye (Lond)
Bailey C, Munk MR, Chaudhary V, Lange C, Oubraham H, Morgan-Warren P, Allmeier H, Machewitz T, Schlief S, Gilbert R, Oesch S, Kirchner M, Hasanbasic Z, Lanzetta P, SPECTRUM study investigators.   +14 more
europepmc   +1 more source

Use of Aflibercept 8 mg for the Treatment of Diabetic Macular Edema in Italy: A Cost-Minimisation Analysis Based on an Indirect Treatment Comparison. [PDF]

Adv Ther
Cortesi PA, Mezghani M, Alshaikheid M, Lunk I, D'Orsi MF, Zurria M, Bandello F.   +6 more
europepmc   +1 more source

Comparative Analysis of Ocular Adverse Events between Aflibercept 8 mg and Faricimab

Ophthalmology Retina
Moiz Lakhani, Marko M. Popovic, Abdullah Al-Ani, Deeksha Kundapur, Tara Gholamian, Emaan Chaudry, Keean Nanji, Nikhil Patil, Alessandro Feo, SriniVas Sadda, David Sarraf, Michael S. Ip, Peter J. Kertes, Rajeev H. Muni, Feisal Adatia, Karim F. Damji, Varun Chaudhary, Bernard R. Hurley   +17 more
openaire   +1 more source

Reducing the Carbon Footprint of Neovascular Age-Related Macular Degeneration Therapy: Environmental Impact of Transitioning to Aflibercept 8 mg. [PDF]

J Ophthalmol
Veritti D, Misciagna M, Teatino C, Pontoni C, Blasutig M, Kuftic M, Pece S, Morsanutto A, Pece A, Lanzetta P.   +9 more
europepmc   +1 more source

Increased intraocular pressure immediately after aflibercept 8 mg intravitreal injection for neovascular age-related macular degeneration. [PDF]

Graefes Arch Clin Exp Ophthalmol
Hashiya N, Maruko I, Maruko R, Kakehashi M, Kawahara K, Nishihara S, Iida T.   +6 more
europepmc   +1 more source

Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases

Eye
Jean-François Korobelnik, Paolo Lanzetta, Charles C. Wykoff, Tien Y. Wong, Xin Zhang, Peter Morgan-Warren, Scott Fitzpatrick, Sergio Leal, Lynne Brunck, Zoran Hasanbasic, Karen W. Chu, Kimberly Reed, Sobha Sivaprasad   +12 more
openaire   +4 more sources

A Matching-Adjusted Comparison of Faricimab and Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.

Ophthalmic Res
Lim JI, Leng T, Siedlecki J, Lupidi M, Wells JA, Keane PA, Nudleman E, Mar F, Gibson K, Margaron P, Tabano D, Bührer C, Holekamp N.   +12 more
europepmc   +1 more source

Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy

Lee, Won Ki, Wong, Tien Y., Chen, Shih-Jen, Sun, Xiaodong, Cheung, Chui Ming Gemmy, Silva, Rufino, Ricci, Federico, Zhang, Xin, Machewitz, Tobias, Schulze, Andrea, Schmidt-Ott, Ursula M., Zhao, Min, Hasanbasic, Zoran, Leal, Sergio, Iida, Tomohira   +14 more
openaire   +1 more source